7.55

0.80% 0.06

Trevi Therapeutics Inc (TRVI)

Overview News Price History Option Chain Financials Discussions Forecast

Trevi Therapeutics Inc stock is traded at $7.55, with a volume of 1.29M. It is up +0.80% in the last 24 hours and up +7.86% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Previous Close:

$7.49

Open:

$7.49

24h Volume:

1.29M

Relative Volume:

0.71

Market Cap:

$919.42M

Revenue:

Net Income/Loss:

$-29.07M

P/E Ratio:

-26.03

EPS:

-0.29

Net Cash Flow:

$-31.85M

1W Performance:

+0.40%

1M Performance:

+7.86%

6M Performance:

+64.13%

1Y Performance:

+173.55%

1-Day Range:

$7.435

$7.78

1-Week Range:

$7.24

$7.78

52-Week Range:

$2.36

$8.11

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name

Trevi Therapeutics Inc

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

203-304-2499

Address

195 CHURCH STREET, NEW HAVEN, CT

Employee

Twitter

@TreviThera

Next Earnings Date

2025-03-18

Latest SEC Filings

TRVI's Discussions on Twitter

Compare TRVI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRVI Trevi Therapeutics Inc	7.55	907.24M	0	-29.07M	-31.85M	-0.29
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-01-25	Initiated	Cantor Fitzgerald	Overweight
May-28-25	Initiated	H.C. Wainwright	Buy
Mar-10-25	Reiterated	Needham	Buy
Mar-10-25	Upgrade	Raymond James	Outperform → Strong Buy
Dec-12-24	Reiterated	H.C. Wainwright	Buy
Sep-09-24	Resumed	Leerink Partners	Outperform
Aug-30-24	Initiated	H.C. Wainwright	Buy
Aug-30-24	Initiated	Raymond James	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-12-23	Initiated	B. Riley Securities	Buy
Nov-22-22	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	BMO Capital Markets	Outperform
Jun-03-19	Initiated	Needham	Buy
Jun-03-19	Initiated	SVB Leerink	Outperform
Jun-03-19	Initiated	Stifel	Buy

View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

Aug 20, 2025

Trevi Therapeutics says Lisa Delfini to resign as CFO on Aug 22 - MarketScreener

Aug 20, 2025

Trevi Therapeutics Inc. Added to Custom Quant Screener TodayMarket Sentiment Report & High Accuracy Trade Signal Alerts - thegnnews.com

Aug 20, 2025

Aug 16, 2025

Can Trevi Therapeutics Inc. outperform in the next rallyQuarterly Risk Review & Weekly Breakout Opportunity Watchlist - thegnnews.com

Aug 16, 2025

Market reaction to Trevi Therapeutics Inc.’s recent newsMarket Weekly Review & Daily Growth Stock Investment Tips - Newser

Aug 16, 2025

What’s next for Trevi Therapeutics Inc. stock price2025 Dividend Review & Reliable Breakout Stock Forecasts - Newser

Aug 16, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by XTX Topco Ltd - Defense World

Aug 16, 2025

Chart based exit strategy for Trevi Therapeutics Inc.2025 Support & Resistance & Fast Entry Momentum Trade Alerts - Newser

Aug 16, 2025

Will Trevi Therapeutics Inc. price bounce be sustainableJuly 2025 Reactions & Safe Capital Growth Tips - Newser

Aug 16, 2025

Using Ichimoku Cloud for Trevi Therapeutics Inc. technicalsMarket Sentiment Summary & Consistent Growth Equity Picks - Newser

Aug 16, 2025

What to expect from Trevi Therapeutics Inc. in the next 30 days2025 Geopolitical Influence & Verified Momentum Stock Watchlist - Newser

Aug 16, 2025

Aug 15, 2025

Real time breakdown of Trevi Therapeutics Inc. stock performanceQuarterly Profit Review & Technical Pattern Based Signals - Newser

Aug 15, 2025

Developing predictive dashboards with Trevi Therapeutics Inc. dataAnalyst Upgrade & Consistent Profit Focused Trading Strategies - Newser

Aug 15, 2025

Sentiment analysis tools applied to Trevi Therapeutics Inc.2025 AllTime Highs & Advanced Swing Trade Entry Alerts - Newser

Aug 15, 2025

Can Trevi Therapeutics Inc. hit a new high this monthQuarterly Earnings Summary & Smart Swing Trading Techniques - Newser

Aug 15, 2025

Has Trevi Therapeutics Inc. formed a bullish divergenceJuly 2025 Recap & AI Based Trade Execution Alerts - Newser

Aug 15, 2025

Aug 14, 2025

Trendline Breach Raises Concern for Trevi Therapeutics Inc. InvestorsInsider Buying & Community Shared Stock Ideas - 선데이타임즈

Aug 14, 2025

Is This the Dip to Buy in Trevi Therapeutics Inc.Portfolio Risk Summary & Reliable Intraday Trade Alerts - classian.co.kr

Aug 14, 2025

Aug 13, 2025

Trevi Therapeutics: Optimism Amid Earnings Call Insights - MSN

Aug 13, 2025

Tick level data insight on Trevi Therapeutics Inc. volatility2025 Historical Comparison & Growth Focused Investment Plans - Newser

Aug 13, 2025

Aug 12, 2025

Healthcare Analysts Offer Insights on Trevi Therapeutics, DENTSPLY SIRONA, and Arrowhead Pharmaceuticals. - AInvest

Aug 12, 2025

Trend analysis for Trevi Therapeutics Inc. this weekWeekly Setup Summary for Risk Controlled Trades - Newser

Aug 12, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 12, 2025

Why Trevi Therapeutics Inc. stock attracts strong analyst attentionForward PE Discount Stocks - classian.co.kr

Aug 12, 2025

JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛

Aug 12, 2025

Aug 11, 2025

Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data - MSN

Aug 11, 2025

Trevi Therapeutics' Promising Developments and Strategic Expansion Bolster Growth Potential. - AInvest

Aug 11, 2025

Promising Developments and Strategic Expansion Bolster Trevi Therapeutics’ Growth Potential - TipRanks

Aug 11, 2025

Aug 10, 2025

Trevi Therapeutics' Path to Sustainable Growth and Value Creation - AInvest

Aug 10, 2025

Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans - uk.finance.yahoo.com

Aug 10, 2025

Trevi Therapeutics (TRVI): A High-Potential Biotech Play in Chronic Cough with a Clear Path to Phase 3 and FDA Alignment - AInvest

Aug 10, 2025

Raymond James Financial Has Lowered Expectations for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - Defense World

Aug 10, 2025

Needham & Company LLC Has Lowered Expectations for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - Defense World

Aug 10, 2025

Aug 09, 2025

Trevi Therapeutics Gears Up For Next Phase After Positive Results - Finimize

Aug 09, 2025

Needham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $22.00 - MarketBeat

Aug 09, 2025

Aug 08, 2025

Summit Therapeutics shares rise 1.53% intraday after Trevi Therapeutics reports positive Phase 2b trial results for Haduvio. - AInvest

Aug 08, 2025

Unlocking Long-Term Value: Trevi Therapeutics' Strategic Capital Efficiency and Robust Clinical Data Drive Phase III Momentum - AInvest

Aug 08, 2025

Transcript : Trevi Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener

Aug 08, 2025

Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics - TipRanks

Aug 08, 2025

Earnings call transcript: Trevi Therapeutics Q2 2025 shows slight EPS beat - Investing.com Australia

Aug 08, 2025